According to DelveInsight’s assessment, the global Irritable Bowel Syndrome (IBS) pipeline comprises 15+ Irritable Bowel Syndrome companies actively developing 20+ Irritable Bowel Syndrome treatment therapies. The report provides an in-depth analysis of clinical trials, therapeutic approaches, mechanisms of action, routes of administration, and the latest research and developmental updates, offering a comprehensive view of the evolving IBS treatment landscape.
DelveInsight’s “Irritable Bowel Syndrome Pipeline Insight, 2025” report provides an extensive overview of the current clinical development landscape and future growth opportunities within the Irritable Bowel Syndrome market. The report delivers a thorough commercial and clinical evaluation of pipeline therapies, spanning from preclinical stages to marketed products. It offers detailed insights into each drug’s mechanism of action, clinical trial progress, regulatory milestones (including NDA approvals, if applicable), and ongoing research and development activities such as technology advancements, collaborations, mergers and acquisitions, funding, designations, and other relevant product updates.
Get Your Free Sample Report on IBS Clinical Trials - Dive Deep into Pipeline Therapies and Market Insights Today @ Irritable Bowel Syndrome Clinical Trials Report
Some of the key takeaways from the Irritable Bowel Syndrome Pipeline Report:
- Irritable Bowel Syndrome Companies across the globe are diligently working toward developing novel Irritable Bowel Syndrome treatment therapies with a considerable amount of success over the years.
- Irritable Bowel Syndrome companies working in the treatment market are P4 Microbiome, Biomica, Invea Therapeutics, Inc., RaQualia Pharma, RedHill Biopharma Ltd., 4D pharma, SV-MMX Cosmo Pharmaceuticals, and others, are developing therapies for the Irritable Bowel Syndrome treatment
- Emerging Irritable Bowel Syndrome therapies such as - P4M01, BMC426, INVA 8002, RQ-00310941, RHB-102, Blautix, Rifamycin, and others are expected to have a significant impact on the Irritable Bowel Syndrome market in the coming years.
- In October 2025, AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC), Inflammatory Bowel Disease and moderately to severely active Crohn's disease (CD).
- In January 2025, the FDA granted tentative approval to Amneal Pharmaceuticals’ 550 mg rifaximin tablets, referencing Bausch Health’s Xifaxan, for treating adults with irritable bowel syndrome with diarrhea (IBS-D).
- In June 2025, AbbVie announced results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Participants (Age 6 to 17 Years) With Irritable Bowel Syndrome With Diarrhea (IBS-D)
- In June 2025, Ardelyx announced results of an Open-Label Long-Term Safety Study of Tenapanor for the Treatment of Irritable Bowel Syndrome With Constipation (IBS-C) in Pediatric Patients 6 to Less Than 18 Years Old
- In October 2024, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a healthcare company specializing in gastrointestinal conditions, is set to present new subgroup analysis findings at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course. The analyses, derived from the primary endpoint of the pivotal Phase III STARS trial, assess the treatment effect of apraglutide based on baseline demographics and disease-specific characteristics in adults with short bowel syndrome with intestinal failure (SBS-IF). The oral presentation, reveals that apraglutide demonstrated a consistent treatment effect across various subgroups, including gender, age, body weight, region, race, ethnicity, and SBS characteristics, such as remnant bowel length. These results complement the previously reported positive outcomes from the pivotal Phase III trial.
- In February 2024, CinPhloro Pharma, part of the CinRx portfolio, is developing CIN-103 as an innovative treatment for irritable bowel syndrome with predominant diarrhea (IBS-D). The company announced that the first participant in its Phase 2 enviva study has been dosed. CIN-103, a novel phloroglucinol formulation designed for long-term use, is a non-opioid small molecule targeting multiple IBS-D mechanisms, including motility, secretion, pain, spasms, and inflammation.
Irritable Bowel Syndrome Overview
Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits, including diarrhea, constipation, or both. It affects the large intestine and is influenced by factors such as gut-brain axis dysfunction, stress, infection, and dietary triggers. Although IBS does not cause structural damage to the intestines, it significantly impacts patients’ quality of life. Diagnosis is typically based on symptom criteria like the Rome IV guidelines. Current management strategies include dietary modifications, lifestyle changes, probiotics, and medications targeting specific symptoms, with ongoing research exploring more targeted and personalized therapies.
Get a Free Sample PDF Report to know more about Irritable Bowel Syndrome Pipeline Therapeutic Assessment - Irritable Bowel Syndrome Medication and Approvals
Emerging Irritable Bowel Syndrome Drugs Under Different Phases of Clinical Development Include:
- BEKINDA (RHB-102): RedHill Biopharma
- P4M01: P4Microbiome
- BMC426: Biomica
- ORP-101: OrphoMed
- INVA 8002: Invea Therapeutics, Inc.
- RQ-00310941: RaQualia Pharma
- RHB-102: RedHill Biopharma Ltd.
- Blautix: 4D pharma
- Rifamycin: SV-MMX Cosmo Pharmaceuticals
Route of Administration
Irritable Bowel Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Molecule Type
Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Irritable Bowel Syndrome Pipeline Therapeutics Assessment
- Irritable Bowel Syndrome Assessment by Product Type
- Irritable Bowel Syndrome By Stage and Product Type
- Irritable Bowel Syndrome Assessment by Route of Administration
- Irritable Bowel Syndrome By Stage and Route of Administration
- Irritable Bowel Syndrome Assessment by Molecule Type
- Irritable Bowel Syndrome by Stage and Molecule Type
DelveInsight's Irritable Bowel Syndrome Report covers around 20+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Irritable Bowel Syndrome product details are provided in the report. Download the Irritable Bowel Syndrome pipeline report to learn more about the emerging Irritable Bowel Syndrome therapies
Some of the key companies in the Irritable Bowel Syndrome Therapeutics Market include:
Key companies developing therapies for Irritable Bowel Syndrome are - Allergan, Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Bausch Health, Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synthetic Biologics, Inc., Astellas Pharma, Inc., and Ardelyx, and others.
Irritable Bowel Syndrome Pipeline Analysis:
The Irritable Bowel Syndrome (IBS) Pipeline Report delivers comprehensive intelligence on the evolving therapeutic landscape, encompassing:
- In-depth profiling of key pharmaceutical companies engaged in the development of IBS therapies, including a consolidated view of the therapeutic assets under their pipelines.
- Categorization of drug candidates across various stages of development—early, mid, and late—providing a clear overview of the clinical progress within the IBS treatment domain.
- Assessment of active, dormant, and discontinued projects, highlighting the focus areas and strategic directions of leading market participants in targeted therapeutic development.
- Evaluation of investigational drugs based on development stage, route of administration, molecular targets, therapy type (monotherapy or combination), mechanism of action, and molecular classification.
- Comprehensive analysis of strategic partnerships and transactions, including company–company and academia–industry collaborations, licensing agreements, and funding activities that drive future advancements in the IBS market.
This report is compiled using data sourced from DelveInsight’s proprietary databases, clinical trial registries, company and academic institution websites, scientific conferences, SEC filings, investor presentations, and verified third-party industry sources.
Download the Comprehensive 2025 IBS Pipeline Insight - Discover Latest Drug Approvals, Therapies, and Market Trends @ Irritable Bowel Syndrome drugs and therapies
Irritable Bowel Syndrome Pipeline Market Dynamics
The growth of the Irritable Bowel Syndrome (IBS) market is primarily driven by the rising prevalence of gastrointestinal disorders, changes in bowel habits, and the increasing impact of unhealthy lifestyles. However, market expansion is hindered by complex diagnostic procedures, limited awareness, and other challenges in early detection and management of the condition.
Scope of Irritable Bowel Syndrome Pipeline Drug Insight
- Coverage: Global
- Key Irritable Bowel Syndrome Companies: P4Microbiome, Biomica, Invea Therapeutics, Inc., RaQualia Pharma, RedHill Biopharma Ltd., 4D pharma, SV-MMX Cosmo Pharmaceuticals, and others
- Key Irritable Bowel Syndrome Therapies: P4M01, BMC426, INVA 8002, RQ-00310941, RHB-102, Blautix, Rifamycin, and others
- Irritable Bowel Syndrome Therapeutic Assessment: Irritable Bowel Syndrome current marketed and Irritable Bowel Syndrome emerging therapies
- Irritable Bowel Syndrome Market Dynamics: Irritable Bowel Syndrome market drivers and Irritable Bowel Syndrome market barriers
Unlock Key Clinical and Commercial Analysis on IBS Pipeline - Access the Full Report and Stay Ahead in the Market @ Irritable Bowel Syndrome Pipeline Assessment and clinical trials
Table of Contents
1. Irritable Bowel Syndrome Report Introduction
2. Irritable Bowel Syndrome Executive Summary
3. Irritable Bowel Syndrome Overview
4. Irritable Bowel Syndrome- Analytical Perspective In-depth Commercial Assessment
5. Irritable Bowel Syndrome Pipeline Therapeutics
6. Irritable Bowel Syndrome Late Stage Products (Phase II/III)
7. Irritable Bowel Syndrome Mid Stage Products (Phase II)
8. Irritable Bowel Syndrome Early Stage Products (Phase I)
9. Irritable Bowel Syndrome Preclinical Stage Products
10. Irritable Bowel Syndrome Therapeutics Assessment
11. Irritable Bowel Syndrome Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Irritable Bowel Syndrome Key Companies
14. Irritable Bowel Syndrome Key Products
15. Irritable Bowel Syndrome Unmet Needs
16. Irritable Bowel Syndrome Market Drivers and Barriers
17. Irritable Bowel Syndrome Future Perspectives and Conclusion
18. Irritable Bowel Syndrome Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services
